Could a mango flavoured pill end intestinal worms?

A new tablet being developed to treat intestinal worms has shown positive results in trials and could help eradicate the parasitic disease, which affects an estimated 1.5 billion people worldwide, researchers have said.

The mango-flavoured pill is a combination of two existing anti-parasitic drugs that, when used together, appear to be very effective in eliminating worms.

These worms are contracted through contact with food or water contaminated with soil contaminated with the eggs of the worms and infection causes gastrointestinal symptoms, malnutrition and anemia.

Researchers say that the pills can help to deal with any future problems and to deal with the disease on a large scale.

These parasites, also known as soil-transmitted helminths (STHs), include whipworm and hookworm and are found in many developing countries where sanitation is poor.

Most of the victims are children and there is no preventive treatment other than good hygiene.

According to the survey, called “LIVE”published in the Lancet, the new tablet can help the most affected countries to achieve the goals set by the organization World Health Organization cure disease.

It is taken as a fixed dose of one tablet or three tablets in consecutive days.

Researchers from eight European and African institutions say it could be a simple way to treat large numbers of people in mass drug programs.

Project leader Prof Jose Muñoz said: “It’s easy to give because it’s just one tablet.

“Also, we believe that combining two drugs with different mechanisms of action will reduce the risk of pathogens,” says Prof Muñoz.

When a person is infected with the virus, the virus settles in the person’s intestines.

Although the drug albendazole is effective in treating some types of sexually transmitted infections, it appears to be less effective in treating others.

During clinical trials involving 1,001 children between the ages of 5-18 in Ethiopia, Kenya and Mozambique, it was found to be very effective in many types of diseases when combined with ivermectin.

However, the researchers said that the effect was not as clear as it was with the threadworm.

Prof. Hany Elsheikha, a parasitologist at the University of Nottingham, said the pills could be “a huge improvement over other drugs” and could be used to fight parasites.

“There are some problems with existing drugs … so this could be a big, big deal.”

However, he said that although the study was “promising”, it had “gaps”.

“We don’t know if the results would be the same in adults, mature people, young children, people in other parts of the world.”

The results of this test were presented to the management in Europe and Africa, and the decisions are expected in early 2025.

Participants are now being recruited to take part in another 20,000-person trial in Kenya and Ghana.

Dr Stella Kepha, a researcher at the Kenya Medical Research Institute who conducted the study said the pills “have great potential to improve the health of the affected population” but “there is work to be done” to spread the treatment.